Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
PMG-1016 in Chronic Kidney Diseases: NCT07615985 Clinical Landscape Report 2026
15 October 2026
NCT07615985 clinical landscape for Chronic Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ONO-3310 in Diabetes Mellitus, Type 2: NCT07619157 Clinical Landscape Report 2026
15 October 2026
NCT07619157 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lorlatinib in ALK positive Non-Small Cell Lung Cancer: NCT07617337 Clinical Landscape Report 2026
15 October 2026
NCT07617337 clinical landscape for ALK positive Non-Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Pembrolizumab in metastatic non-small cell lung cancer: NCT07619599 Clinical Landscape Report 2026
15 October 2026
NCT07619599 clinical landscape for metastatic non-small cell lung cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Zorifertinib in Central Nervous System Diseases: NCT07620951 Clinical Landscape Report 2026
15 October 2026
NCT07620951 clinical landscape for Central Nervous System Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[161Tb]Tb PSMA I&Tc in Metastatic castration-resistant prostate cancer: NCT07621692 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_14_36b6ffee12.jpg)
9 min read
[161Tb]Tb PSMA I&Tc in Metastatic castration-resistant prostate cancer: NCT07621692 Clinical Landscape Report 2026
15 October 2026
NCT07621692 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Clazakizumab in Kidney Failure, Chronic: NCT07619820 Clinical Landscape Report 2026
15 October 2026
NCT07619820 clinical landscape for Kidney Failure, Chronic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Esophageal Carcinoma: NCT07632079 Clinical Landscape Report 2026
15 October 2026
NCT07632079 clinical landscape for Esophageal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Alflutinib Mesylate in EGFR positive non-small cell lung cancer: NCT07622706 Clinical Landscape Report 2026
15 October 2026
NCT07622706 clinical landscape for EGFR positive non-small cell lung cancer: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Pembrolizumab in TROP2 NMR-positive non-small cell lung cancer: ISRCTN15819396 Clinical Landscape Report 2026
15 October 2026
ISRCTN15819396 clinical landscape for TROP2 NMR-positive non-small cell lung cancer: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tepotinib Hydrochloride Hydrate in Non-Small Cell Lung Cancer: NCT07619339 Clinical Landscape Report 2026
15 October 2026
NCT07619339 clinical landscape for Non-Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Simvastatin in Metastatic gastroesophageal adenocarcinoma: NCT07625930 Clinical Landscape Report 2026
15 October 2026
NCT07625930 clinical landscape for Metastatic gastroesophageal adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…